Depression in patients with type 2 diabetes: Impact on adherence to oral hypoglycemic agents

Annals of Pharmacotherapy

Volumn 40, Issue 4, 2006, Pages 605-611

  Kalsekar, Iftekhar D ^a   Madhavan, Suresh S ^b   Amonkar, Mayur M ^c   Makela, Eugene H ^b   Scott, Virginia G ^b   Douglas, Stratford M ^b   Elswick, Betsy L Meredith ^b  

^a BUTLER UNIVERSITY   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Adherence; Administrative claims data; Depression; Medicaid; Oral hypoglycemic agents

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; MEGLITINIDE; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; COHORT ANALYSIS; DEPRESSION; DIABETES MELLITUS; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; MENTAL DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADMINISTRATION, ORAL; COHORT STUDIES; DEPRESSION; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES;

EID: 33646254164     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G606     Document Type: Article

References (27)

1. UKPDS Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type-2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
2. Diehl AK, Bauer RL, Sugarek N. Correlates of medication compliance in non-insulin dependent diabetes mellitus. South Med J 1987;80:332-5.
3. Chousa FP, Guillen VFG, Otero MD, Beltran DO, Lopez RP, Sanchez JM. [Usefulness of six indirect methods to evaluate drug therapy compliance in non-insulin dependent diabetes mellitus] Spanish. Rev Clin Esp 1997;197:555-9.
4. Peterson GM, McLean S, Senator GB. Determinants of patient compliance, control, presence of complications, and handicap in non-insulin dependent diabetes. Aust N Z J Med 1984;14:135-41.
5. Shectman JM, Nadkarni MM, Voss JD. The association between diabetes metabolic control and drug adherence in an indigent population. Diabetes Care 2002;25:1015-21.
6. Howard T, Stang P, Lydick E. Increased morbidity and mortality associated with discontinuation of oral antidiabetic therapies (abstract). Presented at: 35th Annual Meeting of the European Association for the Study of Diabetes, Brussels, Belgium, September 28-October 2, 1999.
7. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care 2004;27:1218-24.
8. Paes AHP, Bakker A, Soe-Agnie CJ. Impact of dosage frequency in patient compliance. Diabetes Care 1997;20:1512-7.
9. Nagasawa M, Smith MC, Barnes JH Jr, Fincham JE. Meta-analysis of correlates of diabetes patients' compliance with prescribed medications. Diabetes Educ 1990;16:192-200.
10. Haynes RB. Determinants of compliance: the disease and the mechanics of treatment. In: Haynes RB, Taylor DW, Sackett DL, eds. Compliance in health care. Baltimore: John Hopkins University Press, 1979:49-62.
11. Rubin RR. Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. Am J Med 2005;118(suppl 5A):27S-34S.
12. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment. Meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000;160:2101-7.
13. Sherbourne CE, Hays RD, Ordway L, DiMatteo MR, Kravitz RL. Antecedents of adherence to medical recommendations: results from the Medical Outcomes Study. J Behav Med 1992;15:447-68.
14. Ciechanowski PS, Katon WJ, Russo JE. Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. Arch Intern Med 2000;160:3278-85.
15. Lin EH, Katon W, Von Korff M, et al. Relationship of depression and diabetes self-care, medication adherence, and preventive care. Diabetes Care 2004;27:2154-60.
16. Venturini F, Nichol MB, Sung JCY, Bailey KL, Cody M, McCombs JS. Compliance with sulfonylureas in a health maintenance organization: a pharmacy record-based study. Ann Pharmacother 1999;33:281-8. DOI 10.1345/aph.18198
17. Quinn L. Pharmacologic management of the patient with type 2 diabetes. Nurs Clin North Am 2001;36:217-42.
18. Rural-Urban Continuum codes (2003). www.ers.usda.gov/Data/ RuralUrbanContinuumCodes (accessed 2004 Feb 4).
19. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.
20. D'Hoore W, Bouckaert A, Tilquin C. Practical considerations on the use of the Charlson comorbidity index with administrative databases. J Clin Epidemiol 1996;49:1429-33.
21. Steiner JF, Koepsell TD, Fihn SD, Inui TS. A general method of compliance assessment using centralized pharmacy records. Description and validation. Med Care 1988;26:814-23.
22. Bocuzzi SJ, Wogen J, Fox J, Sung JC, Shah AB, Kim J. Utilization of oral hypoglycemic agents in a drug-insured US population. Diabetes Care 2001;24:1411-5.
23. Spoelstra JA, Stolk RP, Heerdink ER, et al. Refill compliance in type 2 diabetes mellitus: a predictor of switching to insulin therapy? Pharmacoepidemiol Drug Saf 2003;12:121-7.
24. Morningstar BA, Sketris IS, Kephart GC, Sclar DA. Trends in oral antihyperglycemic and insulin use in the Nova Scotia senior population (1993-1999). Can J Clin Pharmacol 2002;9:123-9.
25. Wang PS, Bohn RL, Knight E, Glynn RJ, Mogun H, Avorn J. Noncompliance with antihypertensive medications: the impact of depressive symptoms and psychosocial factors. J Gen Intern Med 2002;17:504-11.
26. Choo PW, Rand CS, Inui TS, et al. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care 1999;37:846-57.
27. Piette JD, Richardson C, Valenstein M. Addressing the needs of patients with multiple chronic illnesses: the case of diabetes and depression. Am J Manag Care 2004;10(2 part 2):152-62.